Trial Profile
To evaluate time to next therapy and duration of therapy of Bortezomib,Carfilzomib and Ixazomib combinations with Lenalidomide/Dexamethasone in patients with relapsed refractory multiple myeloma
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 26 Dec 2017
Price :
$35
*
At a glance
- Drugs Bortezomib (Primary) ; Carfilzomib; Dexamethasone; Ixazomib; Lenalidomide
- Indications Multiple myeloma
- Focus Therapeutic Use
- 26 Dec 2017 New trial record
- 12 Dec 2017 Results presented at the 59th Annual Meeting and Exposition of the American Society of Hematology